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Summary
Objective: To determine the capacity of human subchondral osteoarthritic osteoblasts (Ob) to produce interleukin (IL)-1, IL-6, transforming
growth factor- (TGF-) and prostaglandin E2 (PGE2), and determine if a relationship exists between IL-1, TGF-, PGE2 and IL-6
production.
Methods: We measured the abundance of IL-1, IL-6, TGF- and PGE2 using very sensitive ELISA in conditioned-media of human primary
subchondral Ob from normal individuals and osteoarthritic patients. Selective inhibition of IL-6 or IL-6 receptor signaling was performed to
determine its effect on PGE2 production whereas the inhibiton of PGE2 production was performed to determine its effect on IL-6 production.
The expression of bone cell markers and urokinase plasminogen activator (uPA) activity was also determined.
Results: Osteoarthritic Ob produced all these factors with greater variability than normal cells. Interestingly, the production of IL-6 and PGE2
by osteoarthritic Ob separated patients into two subgroups, those whose Ob produced levels comparable to normal (low producers) and
those whose Ob produced higher levels (high producers). In those cells classified as high osteoarthritic Ob, PGE2 and IL-6 levels were
increased two- to three-fold and five- to six-fold, respectively, compared with normal. In contrast, while using their IL-6 and PGE2 production
to separate osteoarthritic Ob into low and high producers, we found that IL-1 levels were similar in normal and all osteoarthritic Ob. Using
the same criteria, TGF- levels were increased in all osteoarthritic Ob compared with normal. Reducing PGE2 synthesis by Indomethacin [a
cyclo-oxygenase (COX) -1 and -2 inhibitor] reduced IL-6 levels in all osteoarthritic Ob, whereas Naproxen (a more selective COX-2 inhbitor)
reduced PGE2 and IL-6 levels only in the high osteoarthritic group. Conversely, PGE2 addition to osteoarthritic Ob enhanced IL-6 production
in both groups. Moreover, the addition of parathyroid hormone also stimulated IL-6 production to similar normal levels in both osteoarthritic
groups. In contrast, using an antibody against IL-6 or IL-6 receptors did not reduce PGE2 levels in either group. The evaluation of alkaline
phosphatase activity, osteocalcin release, collagen type I and uPA activity in osteoarthritic Ob failed to show any differences between these
cells regardless to which subgroup they were assigned.
Conclusions: These results indicate that IL-6 and PGE2 production by subchondral Ob can discriminate two subgroups of osteoarthritic
patients that cannot otherwise be separated by their expression of cell markers, and that endogenous PGE2 levels influence IL-6 synthesis
in osteoarthritic Ob. © 2002 OsteoArthritis Research Society International. Published by Elsevier Science Ltd. All rights reserved.
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Recent clinical and fundamental findings suggest that the
function of subchondral osteoblasts (Ob) may be perturbed
in osteoarthritis (OA). We still do not fully understand the
etiology, pathogenesis and progression of this disease1,2.491Although this disease can be described as the degradation
and loss of articular cartilage3,4, specific interactions
between subchondral bone and cartilage in OA have been
suggested. For example, factor(s) produced by osteo-
arthritic subchondral Ob can directly modify glycos-
aminoglycan content of normal articular cartilage5 yet the
exact mechanisms and factors involved still remain poorly
understood.
Bone is a rich source of growth factors that play key roles
in the regulation of the formation and resorption of this
tissue. Ob produce insulin-like growth factors (IGFs) and
the transforming growth factor- (TGF-) family of peptides
including bone morphogenetic proteins (BMPs). Ob also
synthesize a number of cytokines that play crucial roles in
skeletal cells6. These include interleukin (IL)-1, -4, -6 and
-11, macrophage and granulocyte/macrophage colony-
stimulating factors, and tumor necrosis factors (TNFs). All
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PATIENTS AND CLINICAL PARAMETERS
Osteoarthritic specimens were obtained from a total of
21 patients (6 males, 15 females) aged 70±7 years
(mean±S.D.) undergoing total knee replacement surgery.
These patients were classified as osteoarthritic according
to the criteria of the American College of Rheumatology15.
Subchondral bone was dissected from tibial plateaus under
sterile conditions as previously described7,8. The patients
were primary OA cases, and they were all considered as
moderate to severe cases. Each specimens were graded 1
to 4 for mild to severe damage (cartilage degradation
and fibrilation, subchondral bone sclerosis, synovial mem-
brane inflammation) and for the presence of osteophytes
(1: none; 2: few; 3: general distribution; 4: numerous
osteophytes) to determine macroscopic variations between
samples. Patients had not received any medication for
6 months prior to surgery that would interfere with bonemetabolism, including corticosteroids. Likewise, non-
steroidal antiinflammatory drugs (NSAIDs) were not taken
by the patients in the week before surgery. Normal tibial
plateaus subchondral bone specimens were collected at
autopsy from five individuals (three males, two females)
aged 67±11 years (mean±S.D.) that had not received
medication interfering with bone metabolism or had
any bone metabolic disease. Only individuals showing
macroscopically normal cartilage were included.SUBCHONDRAL BONE PRIMARY Ob CELL CULTURES
The subchondral bone plate of the medial tibial plateaus
were dissected out and cell cultures were prepared as
previously described7,8,16,17 using sequential digestion of
bone pieces in the presence of collagenase type I (Sigma,
St Louis, MO). Bone pieces were then distributed in T25
flasks and cultured in BGJb media containing 20% fetal
bovine serum (FBS, Wisent Inc, St. Bruno, Quebec) and
this medium was replaced every 2 days until cells were
observed in the petri dishes. The culture medium was then
replaced with fresh media containing 10% FBS. The time of
appearance of cell outgrowths between normal and osteo-
arthritic preparations was similar, as was the time to reach
confluence (mean±S.D.: 33±8 vs 37±9 days for normal and
osteoarthritic Ob respectively). At confluence cells were
split once and plated at 25,000 cells/cm2 in 24 wells
(Falcon, Lincoln Park, NJ) then grown for 5 days to reach
confluence again. We have previously demonstrated that
cells obtained under these culture conditions show an
Ob-like cell phenotype8,16,17. Confluent cells were then
incubated for 2 days in serum free HAMF12/DMEM media
(Sigma) containing 1% insulin-transferrin-selenium mix
(ITS, Sigma). These conditioned media were collected at
the end of the incubation and frozen at −80°C prior to
assays. Cells were washed twice with PBS pH 7.4 and
solubilized in an alkaline phosphatase buffer consisting of
100 mM glycine, 1 mM MgCl2, 1 mM ZnCl2, 1% Triton
X-100, pH 10.5 for 60 min with agitation at 4°C. Cell lysates
were used for alkaline phosphatase activity17 and protein
determination by the bicinchoninic acid method18.DETERMINATION OF IL-1, IL-6, TGF- AND PGE2
Cytokines, TGF-1 and PGE2 levels were determined in
supernatant of confluent cells incubated for their last 48 h
of culture in HAMF12/DMEM media containing 1% ITS.
IL-1, IL-6 and total TGF-1 levels were determined using
highly specific Quantikine ELISA assays from R&D Sys-
tems (Minneapolis, MN). The sensitivities of the assays
were 0.029 pg/ml, 0.7 pg/ml and 7 pg/ml respectively.
PGE2 was determined using a highly specific ELISA assay
from Cayman Chemicals (Ann Arbor, MI) and the sensitivity
was 15 pg/ml. All ELISAs are very specific assays that do
not cross react with related cytokines/prostaglandins
when tested at saturating concentrations. Determinations
were performed in quadruplicate for each cell culture
preparation.RELATIONSHIP BETWEEN IL-6 AND PGE2 LEVELS
As IL-6 and PGE2 levels have been shown to be related
in different Ob cell models, we next wanted to evaluate if a
similar trend would be present in osteoarthritic Ob. We
addressed this question by first inhibiting PGE synthesis inof these have important effects in bone remodeling, and
stimulate bone resorption via the recruitment/activation of
osteoclasts. However, available data on growth factors and
cytokines produced by osteoarthritic subchondral bone
cells is poor. Osteoarthritic Ob from subchondral bone have
unique metabolic behavior in vitro7,8 and in vivo9,10. Osteo-
arthritic Ob show increased metabolic activities compared
to normal Ob, a situation not related to the state of cartilage
erosion nor to the actual site where bone pieces were
collected from the tibial plateau8,11. These features include
high alkaline phosphatase and urokinase plasminogen acti-
vator (uPA) activities7,8,10, elevated collagen produc-
tion9,10, increased release of osteocalcin and production of
IGF-18 compared with normal. Moreover, in vivo IGF-1,
IGF-2 and TGF- levels were shown to be elevated at bone
sites distant from weight-bearing joints in osteoarthritic
patients12 suggesting that generalized bone alterations are
important in OA. These factors are regulated in bone tissue
by cytokines produced locally, and it is now well recognized
that proinflammatory cytokines, such as IL-1 and TNF-,
as well as prostaglandins (PGs), especially PGE2, are
involved in the inflammatory process of OA.
Two studies relevant to OA/rheumatoid arthritis origin
have reported data for cytokine production from Ob pre-
pared from subchondral trabecular bone5,13. However, no
clear trend has been established in these studies. This may
be linked to the cell culture conditions, time in culture,
assay conditions or comparison between different bone
sites. Interestingly, Ob obtained from either hip or knee
joints of osteoarthritic patients showed different capacities
to degrade glycosaminoglycans5. Recent studies from our
group indicated that chondrocytes from osteoarthritic
patients could produce endogenous low or high levels of
collagenase-3, and these two groups of cells responded
differently to cytokine stimulation14.
The integrity of the overlying cartilage in the joint space
is maintained by a fine balance between anabolic/catabolic
factors produced locally. The subchondral bone growth
plate is in direct contact with the cartilage and could
influence its degradation/remodeling. The aims of this
study were to investigate the capacity of osteoarthritic
subchondral Ob to produce IL-1, IL-6, TGF- and PGE2,
and to compare their production to that of normal Ob, and
to examine if a relationship exists between the levels of
IL-1, TGF-, PGE2 and IL-6 levels in osteoarthritic Ob.2
Osteoarthritis and Cartilage Vol. 10, No. 6 493osteoarthritic cells with two inhibitors of cyclo-oxygenase
(COX): Indomethacin (COX-1 and -2 inhibitor, 30 g/ml;
Sigma), or Naproxen (more selective COX-2 inhibitor,
90 g/ml; Sigma), during the last 48 h of incubation.
Second, we tested whether inhibiting IL-6 signaling would
prevent PGE2 synthesis using a neutralizing IL-6 receptor
antibody (100 g/ml; R&D Systems Inc, Minneapolis, MN)
or with an inactivating-IL-6 antibody (10 g/ml; R&D Sys-
tems). Further, we evaluated the direct role of PGE2 on IL-6
synthesis by OA Ob. Cells were stimulated with either 5 nM
or 500 nM PGE2 (Sigma) or 100 nM PTH (Peninsula,
Belmont, CA) as a positive control, for the last 48 h of
incubation.PHENOTYPIC CHARACTERIZATION OF Ob AND ACTIVITY OF
UROKINASE PLASMINOGEN ACTIVATOR
Phenotypic features of all Ob cultures were determined
by evaluating 1,25(OH)2D3-dependent (50 nM) alkaline
phosphatase activity and osteocalcin release, and uro-
kinase plasminogen activator (uPA) activity. Alkaline phos-
phatase activity and osteocalcin release were determined
as we previously described7,8,17. To determine the activity
of uPA, we used the procedure of Leprince et al.19 that
detects the release of p-nitroaniline from the hydrolysis of
the specific substrate DL-Val-Leu-Arg-p-nitroanilide
(Sigma) at 405 nm.SEMI-QUANTITATIVE RT-PCR OF COLLAGEN TYPE I AND TYPE II
Osteoblasts were incubated for the last 24 h of culture
with serum-free HamF12/DMEM media. At the end of the
incubation, cells were washed twice with PBS and scraped
into Trizol lysing solution (Gibco BRL, Burlington, Ontario,
Canada). Total RNA was extracted by the method of
Chomczynski and Sacchi20, and 0.5 g of mRNA used for
RT-PCR amplification as previously described21. A 461
base pairs cDNA probe for collagen type I and 621 base
pairs cDNA probe for collagen type II was generated via
PCR based amplification using 20 pmol of each primer
(sense) 5′-GGA CAC AAT GGA TTG CAA GG-3′ and
5′-AAC TGG CAA GCA AGG AGA CA-3′ and (antisense)
5′-TAA CCA CTG CTC CAC TCT GG-3′ and 5′-AGT TTC
AGG TCT CTG CAG GT-3′ for collagen type I and type II
respectively22,23. Preliminary experiments showed that,
using 35 cycles, we were still in the linear portion of the
amplification procedure. GAPDH was used as a house-
keeping gene amplified using 20 pmol of primers (sense)
5′-CAG AAC ATC ATC CCT GCC TCT-3′ and (antisense)
5′-GCT TGA CAA AGT GGT GGT TGA-3′. RNA extracted
from human articular cartilage was used as a positive
control for collagen type II amplification, and from human
osteosarcoma MG-63 cells for collagen type I amplification.
Specimens were then visualized on an agarose gel.STATISTICAL ANALYSIS
All the results are expressed as the mean±S.E.M., except
for Fig. 1 where data for normal Ob are given as the
mean±2 S.D. and individual values for PGE2 and for IL-6
levels are given for osteoarthritic Ob. Statistical analysis
was performed by the two-tailed Mann–Whitney U-test for
individual determinations and a difference of 0.05 was
considered significant. The correlation between parameters
was determined by simple linear regression analysison individual data using the GB-Stat 6.5 software for
Macintosh and P values less than 0.05 were considered
significant.ResultsDETERMINATION OF IL-1, IL-6, TGF- AND PGE2
Experiments revealed that subchondral Ob from normal
and osteoarthritic individuals produced detectable levels of
IL-1, IL-6, TGF- and PGE2. Levels for normal Ob were
close together while osteoarthritic Ob showed wider varia-
tions. Figure 1(a) shows the mean value±2 S.D. for normal
and the individual values for each osteoarthritic Ob cell
cultures for PGE2 and IL-6 levels. Of note, PGE2 and IL-6
levels in osteoarthritic Ob are distributed within two different
groups. One group showed similar values to normal Ob and
was designated as low producers, and the other group
consistently showed values that were above the
mean±2 S.D. value of normal PGE2 and IL-6 levels, desig-
nated high producers. The high producers showed signifi-
cantly elevated PGE2 levels [two- to four-fold compared to
normal, N=8, P<0.005, Fig. 1(b)] and IL-6 levels [three- to
six-fold compared to normal, N=8, P<0.005 Fig. 1(c)]. In
contrast, when IL-1 and TGF- levels for the same
patients were analysed, they did not show a similar trend
(Fig. 2). IL-1 levels from osteoarthritic Ob were not signifi-
cantly different from normal even when they were separ-
ated according to their PGE2 and IL-6 levels between low
and high producers (Fig. 2). TGF- levels from all osteo-
arthritic Ob were statistically higher than normal regardless
of whether these cells produced high or low levels of PGE2
and IL-6 (Fig. 2).RELATIONSHIP BETWEEN IL-6 AND PGE2 PRODUCTION
Previous studies have shown that IL-6 production in
osteoblasts is stimulated by IL-1, PGE2 and TGF-, and
that IL-1 and TGF- use a prostaglandin-dependent path-
way to promote IL-6 synthesis24,29. As IL-1 levels are not
significantly different in osteoarthritic Ob compared with
normal, this would preclude that it could affect IL-6 produc-
tion. However, to confirm this hypothesis, cells were incu-
bated in the presence of IL-1 receptor antagonist (10 g/ml,
R&D Systems, Minneapolis, MN), and this treatment failed
to inhibit PGE2 synthesis in osteoarthritic Ob (data not
illustrated).
As total TGF-1 levels were high for all osteoarthritic Ob,
this could translate into overall stimulation of IL-6 produc-
tion in all osteoarthritic Ob, if biologically active TGF-1
levels follow total TGF-1 levels in these cells. However,
our data showed no relationship between IL-6 levels and
TGF-1 levels in these cells (data not illustrated). In con-
trast, a positive linear relationship was observed between
IL-6 and PGE2 levels in osteoarthritic Ob (1039+0.5584x,
correlation coefficient 0.5382, two-tailed probability
P<0.04). We pursued by investigating whether endogen-
ous PGE2 levels would be high enough to promote IL-6
production. We evaluated the levels of PGE2 and IL-6: (i)
under basal conditions to identify high and low producers
and (ii) following the inhibition of their production and/or cell
signaling with indomethacin, Naproxen or IL-6 antibodies.
As shown in Fig. 1, PGE2 levels were about two- to
three-fold higher in the high osteoarthritic producers, and
both Indomethacin and Naproxen blocked PGE2 release by
about 50% [Fig. 3(a)]. Conversely, Naproxen was without
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Fig. 1. (a) Production of PGE2 and IL-6 by human subchondral osteoblasts of normal (N=5) and osteoarthritic (N=15) patients. PGE2 and
IL-6 were determined using sensitive ELISA assays. Individual values for each osteoarthritic patient are presented, and PGE2 and IL-6
values for the same patient are linked together. Filled circles correspond to the mean value obtained with five normal osteoblasts (Ob)±2
standard deviations. Filled squares correspond to osteoarthritic patients with PGE2 values two to four fold higher and IL-6 values three- to
six-fold higher than normal (N=8); open circles correspond to osteoarthritic patients with values similar to normal individuals (N=7). (b)
Mean±S.E.M. PGE2 levels by human subchondral bone osteoblasts of normal (N=5), low osteoarthritic (N=7) and high osteoarthritic (N=8)
patients as determined in (a). (c) Mean±S.E.M. IL-6 levels by human subchondral osteoblasts of normal (N=5), low osteoarthritic, (N=7) and
high osteoarthritic (N=8) patients as determined in (a). ###P<0.01 vs normal.0
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Fig. 2. Production of IL-1 (a) and TGF-1 (b) by human subchondral osteoblasts of normal (N=5), low osteoarthritic (N=7) and high
osteoarthritic (N=8) patients as detemined in Fig. 1. Values are presented as the mean±S.E.M. #P< 0.05 vs normal.
Osteoarthritis and Cartilage Vol. 10, No. 6 495effect in the low osteoarthritic group whereas Indomethacin
reduced its production by about 40%. Cells treated with an
antibody against IL-6 abrogated IL-6 production [Fig. 3(b)]
but failed to significantly affect PGE2 levels in both groups[Fig. 3(a)]. Identical results were observed when an anti-
IL-6 receptor was used (data not illustrated). Interestingly,
IL-6 levels were affected both by Naproxen and Indo-
methacin treatments in the high osteoarthritic producers
[Fig. 3(b)], while although Naproxen reduced IL-6 levels
slightly in the low osteoarthritic Ob, only Indomethacin
treatment reached significance [Fig. 3(b)].
As our previous results showed that blocking PGE2
synthesis inhibited IL-6 production in all osteoarthritic Ob,
we then assessed the effect of exogenous PGE2 addition
on the levels of IL-6 in each osteoarthritic group. As the
levels of endogenous PGE2 reached concentrations in the
nM range in the high osteoarthritic producers, we stimu-
lated osteoarthritic Ob with either 5 nM PGE2 in order to
mimic the situation observed in the high osteoarthritic
producers, or with 500 nM PGE2 to maximally stimulate
these cells. Positive controls were also performed using
100 nM PTH stimulation, which is a known promoter of
IL-6 synthesis in Ob30–34. Figure 4 illustrates that PTH
stimulated IL-6 production in both osteoarthritic groups tosimilar levels. PGE2 addition significantly stimulated IL-6
production in both groups but to a different extent. In low
osteoarthritic Ob producers, the addition of 5 nM PGE2
stimulated IL-6 levels two-fold and reached levels similar to
the high osteoarthritic responders under basal condition. In
the high osteoarthritic Ob responders, 5 nM PGE2 stimu-
lated IL-6 only about 20% above their initial levels. In
contrast, the addition of 500 nM PGE2 strongly enhanced
IL-6 levels to similar values in cells of both osteoarthritic
groups, and IL-6 levels were above those reached with
PTH alone (Fig. 4). These results indicate that maximal
doses of PTH and PGE2 stimulate IL-6 synthesis to similar
levels in both groups despite high initial IL-6 production in
high osteoarthritic producers.0
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Fig. 3. Modulation of PGE2 (a) and IL-6 (b) production in low (N=4)
and high (N=8) osteoarthritic human subchondral osteoblasts.
Confluent primary Ob were incubated for their last two days of
culture in HAMF12/DMEM media containing 1% ITS in the
presence or absence of Indomethacin (30 g/ml; ), Naproxen
(90 g/ml; ), IL-6 neutralizing antibody (10 g/ml, IL-6 Ab; ), or
vehicle (basal; ). PGE2 values are presented as the mean±S.E.M.
####P<0.005 vs basal value from respective subgroup. IL-6
values are presented as the mean±S.E.M. #P<0.05, ##P<0.02,
#####P<0.001 vs basal value from respective subgroup.0
10 000
##
##
High OALow OA
6000
4000
2000
IL
-6
 (
pg
/m
g 
pr
ot
ei
n
) 8000
###
##
###
##
###
##
Fig. 4. Modulation of IL-6 production by PTH and PGE2 in low(N=4) and high (N=5) osteoarthritic primary human subchondral
osteoblasts. Ob were incubated as in Figs 4 and 5 except cells
were treated with 100 nM PTH ( ), 5 ( ) or 500 nM PGE2 ( ), or
the vehicle (basal; ). IL-6 was determined using a sensitive
ELISA and values are presented as the mean±S.E.M. ##P<0.02,
###P<0.01, ####P<0.005 and #####P<0.001 vs basal value from
respective subgroup.PHENOTYPIC DETERMINATION OF NORMAL AND OSTEOARTHRITIC
Ob AND uPA ACTIVITY
Osteoarthritic Ob from both groups showed higher than
normal 1,25(OH)2D3-induced alkaline phosphatase activity
and osteocalcin release (Fig. 5) as we previously
observed8. Interestingly, no differences between the high
and low producers were found in terms of these phenotypic
markers (Fig. 5). The evaluation of uPA activity in the
supernatants of these cells using the hydrolysis of a selec-
tive substrate also showed no differences between the low
and high producers. Activities of 1565.2±372 and
1557.5±366.6 nmol/mg protein/24 h for the low and high
producer groups respectively were found, compared with
1080.3±224.4 nmol/mg protein/24 h for normal Ob. This
further suggests that not all metabolic activities are altered
between these two groups of Ob. Figure 6 illustrates
RT-PCR experiments for the expression of collagen type I
and II in normal and osteoarthritic Ob preparations. Data
indicate that Ob express high levels of collagen type I
whereas they did not express collagen type II.
Finally, the differences observed between the two sub-
groups of osteoarthritic patients could not be related to
clinical parameters. Indeed, the macroscopic grading and
evaluation of osteophytes of all 21 osteoarthritic patients
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Fig. 5. Evaluation of phenotypic markers of normal (N=5; ), low (N=7; ) and high (N=8; ) osteoarthritic human subchondral osteoblasts.
Confluent primary osteoblasts were incubated for their last two days of culture in HAMF12/DMEM containing 2% charcoal-treated FBS and
50 nM 1,25(OH)2D3. Osteocalcin release was determined on aliquots of conditioned media by an EIA assay whereas alkaline phosphatase(ALPase) activity was determined by the hydrolysis of p-nitrophenyl phosphate into p-nitrophenol. Values are the mean±S.E.M. ##P<0.02,
###P<0.01 vs respective normal value.Fig. 6. RT-PCR of collagen type I and type II expression by normal and osteoarthritic human subchondral osteoblasts. Confluent primary
osteoblasts (one normal and two osteoarthritic Ob) were incubated for their last two days of culture in HAMF12/DMEM with 1% ITS. Cells
were lysed using Trizol and total RNA extracted prior to RT-PCR. Positive controls were human MG-63 cells for collagen type I and human
articular chondrocytes for collagen type II. GAPDH was used as a reference housekeeping gene.
Osteoarthritis and Cartilage Vol. 10, No. 6 497failed to indicate any trend when assigned to their respec-
tive subgroup. The macroscopic grading was similar
(2.7±0.5 vs 3.0±0.5) as well as the evaluation of osteo-
phytes (2.3±1.0 vs 2.6±0.9) were similar and statistically
not different for the low and high producers, respectively.Discussion
This study is the first to demonstrate variable cytokine
levels in in vitro osteoarthritic subchondral osteoblasts
isolated from the subchondral bone growth plate compared
with no significant differences with osteoarthritic Ob pre-
pared from trabecular bone pieces5,13, a situation that may
be due to the sensitivity of the ELISA used in these studies.
It is also the first demonstration of variable cytokine levels
by Ob prepared from osteoarthritic patients considered
clinically similar (severity, disease duration, macroscopic
evaluation). The emerging concept is that one group of
osteoarthritic patients (designated as low producers) may
be considered as presenting normal levels of IL-6 and of
PGE2. Conversely, another group of osteoarthritic patients(designated as high producers) demonstrated an enhanced
capacity to produce IL-6 and PGE2. A recent study with
trabecular bone cell cultures from osteoarthritic patients
showed a ∼five-fold increase in IL-6 mRNA and protein
expression compared with normal Ob, yet these cells also
failed to produce IL-1 above normal levels35.
Markers of bone cell activity were not different between
the two subgroups (alkaline phosphatase, osteocalcin, col-
lagen type I expression, uPA activity) yet are different from
normal, a situation also previously reported by our group7,8.
Hence, the alterations in PGE2 and IL-6 synthesis could not
be due to altered cell integrity, culture conditions and/or
cellular response. Moreover, the macroscopic evaluation of
the specimens from our patients could not discriminate
between the two subgroups nor was there any relationship
between the presence of osteophytes and the assigned
subgroup.
The initiating event responsible for the degradation of
cartilage in osteoarthritic patients is still elusive, yet the
involvement of the subchondral bone tissue in this process
is gaining support5,8–10,12. A plausible hypothesis could be
that cytokines/growth factors/prostaglandins produced
locally by subchondral bone tissue may seep through the
bone–cartilage interface and stimulate cartilage break-
down. Indeed, considerable evidence indicates the pres-
ence of channels and fissures between cartilage and bone
providing a route for biological signals between these
compartments36–38. In this respect, if the abnormal produc-
tion of proinflammatory cytokines and prostaglandins
observed here for osteoarthritic Ob reflects the in vivo
situation in the subchondral compartment, this could influ-
ence the overlying cartilage in osteoarthritic individuals.
It is surprising that IL-1 synthesis was not significantly
elevated in the high osteoarthritic producers as this
cytokine has been described as a key regulator of inflam-
mation in osteoarthritic joints39,40. IL-1 plays an important
role in bone metabolism and is involved in bone resorption
as are PGE2 and IL-6. Some osteoarthritic patients show
abnormally low mineralization pattern in bone explants of
the femoral head9,41 and clinical indices of bone resorption
are increased in osteoarthritic patients35,42,43. This sug-
gests that other effectors besides IL-1 must be controlling
the synthesis of PGE2 and IL-6. Moreover, as total TGF-1
levels are elevated in all osteoarthritic Ob compared to
normal but not all osteoarthritic Ob showed elevated PGE2and IL-6 levels, this would preclude that TGF-1 could be
an important autocrine/paracrine factor for PGE2 and/or
IL-6 production in in vitro osteoarthritic Ob. We evaluated
total TGF-1, a situation that may not be similar for free
TGF-1. However we previously showed that free and total
TGF-1 levels were both elevated in osteoarthritic bone
explants11. Conversely, endogenous free TGF- levels,
albeit higher than normal, could fail to reach high enough
levels to influence PGE2 synthesis and therefore IL-6
synthesis. However, since TGF-1 promotes osteophyte
formation in knee joints44,45 and there were no significant
differences in osteophyte distribution between our osteo-
arthritic specimens, this would indicate that TGF-1
reached high enough levels in vivo to promote its biological
effects. This would then suggest that endogenous TGF-1
in osteoarthritic Ob is not stimulating IL-6 production.
The data with Naproxen in osteoarthritic Ob could sug-
gest that PGE2 levels in high producers were the result of
enhanced COX-2 activity in these cells whereas Naproxen
was without significant effect in the low producers.
However, both groups of osteoarthritic Ob responded to
Indomethacin, indicating the participation of both COX-1
and/or -2 in their PGE2 production. Conversely, IL-6, which
also triggers bone resorption, was present at very high
levels in the high osteoarthritic producers. Our data
strongly suggests that elevated endogenous PGE2 levels is
a key modulator of IL-6 levels in osteoarthritic Ob. First, the
inhibition of endogenous PGE2 synthesis by osteoarthritic
Ob prevented IL-6 production only in the high producers.
Previous studies have reported that PGE2 can directly
affect IL-6 production in mouse and rat bone cultures46,47,
and that the cAMP-PKA-dependent pathway is involved in
this response48. Second, endogenous PGE2 levels were
high enough in the high osteoarthritic producer group to
stimulate IL-6 synthesis, and correlate with IL-6 levels in
osteoarthritic Ob. Indeed, the addition of PGE2 (5 nM)
stimulated IL-6 production in low osteoarthritic producers to
similar levels as the high producers whereas the same
treatment failed to influence IL-6 production in the high
producers. This difference in IL-6 production could be
explained by homologous desensitization to chronic PGE2
exposure in the high producers. In contrast, PTH which
directly stimulates IL-6 production enhanced IL-6 levels in
all osteoarthritic Ob to similar levels regardless of their
initial endogenous production of PGE2. Moreover, addition
of higher levels of PGE2 (500 nM) stimulated IL-6 synthesis
to even higher levels than PTH in both groups, suggesting
that desensitization was circumvented by a challenge with
higher doses of PGE2.
TGF-1 levels in osteoarthritic Ob were higher than
normal yet similar for all osteoarthritic Ob. This agrees with
previous data from our laboratory that showed that free and
total TGF-1 levels were higher in osteoarthritic sub-
chondral bone explants vs normal11. However, elevated
TGF-1 and IGF-1 levels7,8 in osteoarthritic Ob may syn-
ergize to produce a positive effect on bone formation. IGF-1
levels are very variable among osteoarthritic subchondral
Ob7,8, albeit significantly different from normal. PGE2 has
been shown to directly stimulate IGF-1 synthesis in
Ob-enriched cultures from fetal rat bone49. Hence, the
variable endogenous PGE2 levels observed in osteoar-
thritic Ob may explain these variations in IGF-1 levels.
Moreover, Dequeker et al. reported increased TGF- levels
in bone explants from non-weight-bearing sites in osteo-
arthritic patients, indicating that increased TGF- levels
was part of the pathophysiology of OA12.
498 F. Massicotte et al.: Altered IL-1, IL-6, TGF- and PGE2 productionWhile the differences observed in this in vitro study could
also result from heterogenous Ob cell populations contami-
nated by marrow stromal cells, chondrocytes, reticulum or
fibroblast-like cell types in long term culture, this is very
unlikely. First, all parameters evaluated within an individual
cell culture should be similarly affected, whereas only PGE2
and IL-6 levels were variable among osteoarthritic patients.
Second, variable cell contaminations should lead to vari-
able levels of bone cell markers between osteoarthritic Ob,
which is not the case. Third, our preparations did not
express collagen type II, a cell marker for chondrocytes, but
expressed only collagen type I, a phenotypic feature of
mature Ob. Lastly, as our Ob are prepared using only the
subchondral bone plate devoid of trabecular remnants and
bone marrow, it would be surprising if marrow stromal cells
could contaminate these preparations. Hence, the different
behavior of osteoarthritic Ob between individual patients
seems to be a genuine feature of these Ob. We also did not
observe any differences in cell growth between normal and
osteoarthritic osteoblasts, a situation that is consistent with
the recent observation that osteoarthritic Ob also show a
normal decline in proliferative capacity as a function of
age50, and the demonstration that aging and osteoporotic
patients show similar number and in vitro proliferative
capacity of osteogenic stem cells51.
In conclusion, this study indicates variable levels of
TGF-, IL-6 and PGE2 synthesis by osteoarthritic subchon-
dral osteoblasts compared with normal, and a link between
endogenous PGE2 levels and IL-6 synthesis. Two groups
of patients can be identified based on their low or high
levels of IL-6 and PGE2 production, a situation that could
not be directly related to any classical clinical parameters.
The exact cause(s) of increased PGE2 levels responsible
for IL-6 synthesis in high osteoarthritic Ob remains to be
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